

Reproducible hepatoprotective effects and clinical translatability of semaglutide in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH



Authors
Michael Feigh, Denise Oró, Nicolas Eskesen, Jacob Nøhr-Meldgaard, Henrik H. Hansen
Gubra, Hørsholm, Denmark

Corresponding author
Michael Feigh - mfe@gubra.dk


Background & Aim
The glucagon-like peptide-1 (GLP-1) analogue semaglutide has been reported to promote resolution of MASH and improve fibrosis stage in a recent clinical phase 3 trial (ESSENCE). The present study aimed to evaluate robustness of outcomes of long-term semaglutide treatment in the GAN diet-induced obese (DIO) mouse model of biopsy-confirmed MASH and fibrosis with reference to clinical endpoints.

Methods
Semaglutide was profiled in three individual GAN DIO-MASH mouse studies. C57BL/6Jrj mice were fed the GAN diet for 34-38 weeks before treatment start. Only animals with biopsy-confirmed MASH (NAFLD Activity Score (NAS) ≥ 5) and fibrosis (stage $\geq F1$) were included and stratified into treatment groups. GAN DIO-MASH mice (n=14-20 per group) received (SC) semaglutide (Sema, 30 nmol/kg) or vehicle (Veh) once daily for 20 weeks (study 1) or 24 weeks (study 2 and 3). Vehicle-dosed chow-fed controls served as healthy controls (Lean). Within-subject comparisons (pre- vs. post-treatment) were performed for NAS and fibrosis stage using the Gubra Histopathological Objective Scoring Technique (GHOST) platform. Terminal quantitative endpoints included plasma/liver biochemistry and quantitative liver histology. Histopathological scoring outcomes in GAN DIO-MASH mice were evaluated against primary histological endpoints applied in clinical trials (resolution of MASH with no worsening of liver fibrosis; ≥ 1 -stage fibrosis improvement without worsening of MASH). Statistical analyses were performed using Dunnett's test one-factor linear model (individual study data), Fisher's exact test (pooled study data, histopathological scores) or one-way ANOVA with Dunnett's post-hoc test (pooled study data, quantitative endpoints). *p<0.1, *p<0.05, **p<0.01, ***p<0.001 compared to corresponding vehicle controls.


6 Quantitative histological markers of steatosis, inflammation, fibrosis & fibrogenesis




1 Study outline




2 Body weight




3 Liver weight & transaminases




4 Plasma total cholesterol & triglycerides



5 NAFLD Activity Score (NAS) & Fibrosis stage



7 Clinical translatability



Conclusion

- Long-term semaglutide therapy in GAN DIO-MASH mice:**
- + Improves body weight, hepatomegaly, transaminases and hypercholesterolemia
 - + Improves NAFLD Activity Score and quantitative histological markers of steatosis and inflammation
 - + Improves fibrosis stage (pooled data), and quantitative histological markers of fibrosis and fibrogenesis

Histological outcomes of semaglutide treatment in GAN DIO-MASH mice are comparable to corresponding topline results reported from the clinical phase 3 trial (ESSENCE)

